David Mantus, Ph.D. is Chief Development Officer at Arsanis, Inc., a clinical stage biotechnology company developing monoclonal antibodies to prevent and treat serious bacterial infections. He has more than 24 years of drug development experience, including clinical, regulatory and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious disease. His work in infectious disease product development has included small molecules, microbiome-based therapeutics, immune globulins, monoclonal antibodies, and vaccines. Dr. Mantus has led teams responsible for all aspects of product development, from pre-IND through global commercialization and partnering. Prior to Arsanis he held leadership roles in development at Seres Health, Cubist Pharmaceuticals, Shire Biologics, and Procter & Gamble Pharmaceuticals.
Dr. Mantus received his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the University of Washington. He was an Associate Professor of Pharmaceutical Sciences at MCPHS University, and is co-author of a book on regulatory affairs, “FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics,” that is currently in its third edition.
Dr. Mantus will be speaking at World Anti-Microbial Resistance Congress USA 2016 on ‘The development of mAbs for the treatment and prevention of infectious disease’. This session will answer the following questions:
- What are the clinical and regulatory challenges to the development of mAbs to treat infections?
- What are the real and potential advantages of mAbs vs. traditional anti-infectives?
- What is the history, current status, and future of mAbs for infections?
To hear from Dr. David Mantus and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC.